

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6500

Title: Management of antiviral drug resistance in chronic hepatitis B

Reviewer code: 01567591

Science editor: Ma, Ya-Juan

Date sent for review: 2013-10-22 18:14

Date reviewed: 2013-12-05 00:30

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Management of antiviral drug resistance in chronic hepatitis B. Comments to authors: This review is an update on the management of HBV resistant variants arising during therapy. In that regard, the table 1 can be view as a guide for selecting the best regimens base on HBV rt-polymerase amino acid sequences. Although there is several review on this topic published every year, this one is short, concise and up-to-date. Therefore I support its publication in WJG. Major comments: -The figures 1 and 2 are already available on the website ?Wikipedia? under HBV. I guess the authors of this review are also the authors of the text on HBV in Wikipedia. If not they should clarified this or change the figures. -The figure 2 could be improved. Indeed, the symbols for the HBV polymerase and HBsAg are too similar in size and color. The mRNA is barely visible. The cccDNA should be labelled in the nucleus as (cccDNA) and not at the bottom of the figure with a big arrow. The discrepancy between red and blue arrows should be explained. -There is no comment on drug toxicity for the different combinations. Minor comments: -First line: {nucleos(t)tide } remove the second ?t?. -Line 27: ?rt? in rt-polymerase should be described. -Page 5, last line: ...and in patients are resistant to both... -Figure 1 is not on focus.

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6500

Title: Management of antiviral drug resistance in chronic hepatitis B

Reviewer code: 00039518

Science editor: Ma, Ya-Juan

Date sent for review: 2013-10-22 18:14

Date reviewed: 2013-12-24 02:14

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input checked="" type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The paper "Management of antiviral drug resistance in chronic hepatitis B" is well written and provides an accurate and complete analysis of this important topic. The figures are of high quality and the table is well organized. Minor change: page 5, line 35: add who after the word patients

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6500

Title: Management of antiviral drug resistance in chronic hepatitis B

Reviewer code: 00058353

Science editor: Ma, Ya-Juan

Date sent for review: 2013-10-22 18:14

Date reviewed: 2013-12-24 19:51

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

Its a very comprehensive paper about resistance to oral drugs in chronic HBV. There are not referencies to IFn and may be the title has to be change refering only to oral drugs.... It's the only suggestion about the acceptance of the paper.

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6500

Title: Management of antiviral drug resistance in chronic hepatitis B

Reviewer code: 00225247

Science editor: Ma, Ya-Juan

Date sent for review: 2013-10-22 18:14

Date reviewed: 2013-12-25 22:37

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input checked="" type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This is well-written, comprehensive and informative review on “management of antiviral resistance in chronic hepatitis B”. Newer information on currently developing agents was provided in this draft. I have several minor comments to improve the quality of the manuscript. Specific comments] 1. The authors reviewed systematically and described most of studies related with antiviral resistance in chronic hepatitis B. However, what the readers need is the summary of data which can be applied to real clinical practice. I would recommend the authors to compare the currently available practice guidelines for management of antiviral resistant-CHB in relation to data described in this manuscript. This should be presented as table or figure. 2. The part of “background to the development of antiviral drug resistance” is long and redundant. This part should be shortened and figure 1 is not necessary. 3. Table or figure to summarize the antiviral efficacy of various rescue therapies (ADV monotherapy, ETV monotherapy, LAM+ADV, LDT+ADV, ETV+ADV) need to be shown. In this regards, the following important articles are missing and should be described in references: 1. Lee JM et al. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. *Antivir Ther.* 2010;15(2):235-41.; 1. Park H et al. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. *World J Gastroenterology* 2013 Nov 21; 19(43):7671-7679. 4. HBV genotype in relation to antiviral response can be referred in the article of Kim BK et al. *Antiviral Therapy* 2011;16(8):1169-86. 5. Table 1: If the content of this table is adopted from other articles, it should be described in the context and beneath the table. 6. The word spacing is wrong in some sentence and thus this need attention.